chemotherapy

Org: SOLTI Cancer Research Group, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Vall d’Hebron Institute of Oncology,

Abstract

Org: Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Gustave Roussy and Paris Saclay University, Faculty of Medicine, Villejuif / Kremlin-Bicêtre, France, Samsung Medical Center, Seoul, South Korea, Asan Medical Center, Seoul, South Korea,

Abstract

Prevalence of recreational and medical cannabis products in Veterans and their interactions with cancer directed pharmacological treatment.

Org: University of Tennessee Health Science Center, University of Tennessee of Health Science Center, Kirkland Cancer Center, Baptist Memorial Hospital - Collierville, Lt. Col. Luke Weathers Jr. VA Medical Center,

Abstract

Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: Results from RATIONALE 305.

Org: The Psychometrics Team, Sheridan, WY, BeiGene (Beijing) Co., Ltd, San Mateo, CA,

Abstract

Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649).

Org: OPEN Health,

Abstract

Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial.

Org: Spanish Breast Cancer Group, Málaga,

Abstract

Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.

Org: Maria Sklodowska-Curie National Cancer Research Institute,

Abstract

Efficacy of immunotherapy retreatment in patients with non-small cell lung cancer receiving consolidative durvalumab.

Org: The University of North Carolina Medical Center,

Abstract

EFFECT-neo: A phase 3 study of pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma.

Org: Beijing TongRen Hospital, Internet Hospital of Tianjin Medical University General Hospital, Tianjin First Central Hospital,

Abstract

Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.

Org: LungenClinic, Grosshansdorf, Germany, Institutul Oncologic Prof Dr Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania, L’institut du Thorax, Nantes, France, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, Hospital Universitario La Fe, Valencia, Spain,

Abstract

Correlation of the combination of CT-derived tumor texture and vessel tortuosity on survival outcomes for immunotherapy but not for chemotherapy in metastatic non-small cell lung cancer (mNSCLC): Results from a CheckMate227 (CM227) subset.

Org: Atlanta Veterans Administration Medical Center,

Abstract

Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE) led to higher response, OS, and PFS in patients with transplant-eligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Roswell Park Comprehensive Cancer Center, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Roswell Park Cancer Institute,

Abstract

Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.

Org: Regeneron Pharmaceuticals, Inc., IQVIA, Amsterdam, Netherlands,

Abstract

A three-arm randomized phase II study of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynecological clear cell carcinoma: DOVE (APGOT-OV7/ENGOT-ov80 study).

Org: National University Cancer Institute, Singapore, Cancer Research UK & University College London Cancer Trials Centre,

Abstract

Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice at several Russian centers.

Org: Moscow Multidisciplinary Clinical Center "Kommunarka" of the Moscow Department of Health, Moscow, Russian Federation, SBIH Moscow Multidisciplinary Clinical Center "Kommunarka" of the Moscow Department of Health, Moscow, Russian Federation, Moscow City Oncology Hospital 62, Moscow, Russian Federation, Moscow City Oncology Hospital 62, Krasnogorskiy Rayon, Russian Federation, Moscow City Clinical Oncology Hospital No. 1, Moscow, Russian Federation,

Abstract

Relationship between immune phenotype and treatment selection of Chemo-IO vs. IO-only in TPS-high NSCLC using hypothetical test-and-control group generation based on survival data extracted from phase III trials.

Org: Oncology Therapeutic Development, Lunit Inc.,

Abstract

NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).

Org: Memorial Sloan Kettering Cancer Center, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Washington University School of Medicine in St. Louis, Washington University School of Medicine,

Abstract

Fecal microbiota transplantation combined with anti-PD-(L)1 inhibitors as first-line maintenance therapy for advanced gastric and non small cell lung cancer.

Org: The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, China, Changzhou Second People’s Hospital, Changzhou, China,

Abstract

Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.

Org: Yamaguchi University Hospital, Fundación Arturo López Pérez, Fred Hutchinson Cancer Center and University of Washington, Life Groenkloof Hospital, Istinye University Liv Hospital,

Abstract

Chemotherapy plus PD-1/PD-L1 inhibitor versus chemotherapy alone in first-line treatment for recurrent or advanced endometrial cancer: A systematic review and meta-analysis of randomized controlled trials.

Org: DASA Oncologia, São Paulo, Brazil, Federal University of Ceará, Fortaleza, Brazil, Hospital São Domingos, São Luís, Brazil, Federal University of São João Del-rei, Divinópolis, Brazil, Federal Univerity of Rio de Janeiro, Rio De Janeiro, Brazil,

Abstract

Safety and preliminary efficacy of different doses of fecal microbiota capsule transplantation combined with anti-PD-1 inhibitor for patients with advanced malignant solid tumors.

Org: State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease,

Abstract

Real-world analysis of inetetamab combined with pyrotinib plus chemotherapy for the treatment of HER2-positive advanced breast cancer: A multi-center retrospective study.

Org: The First Hospital of Chongqing Medical University Affiliated Hospital, Zhangjiakou First Hospital, Guiyang Maternal and Child Health Hospital, Yancheng First People's Hospital,

Abstract

Immune checkpoint inhibitor plus chemotherapy versus chemotherapy alone in HER2-negative advanced gastric or gastroesophageal junction cancer: A systematic review and meta-analysis of randomized controlled trials.

Org: Federal Univerity of Rio de Janeiro, DASA Oncologia, Federal University of Ceará, Clion Clínica de Oncologia, Hospital São Domingos,

Abstract

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.

Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Harbin Medical University Cancer Hospital,

Abstract

Targeting glioma stem cells with thyroid hormone suppression: Phase 1/2 trial of methimazole in patients with progressive grade 4 gliomas.

Org: Cleveland Clinic Lerner College of Medicine,

Abstract

Real world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer.

Org: Ballarat Health Services, Royal Hobart Hospital, South West Regional Cancer Centre, Cairns and Hinterland Health,

Abstract

Molecular imaging research on 18F-FDG PET/CT and biomarker analysis to predict the efficacy of neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIB NSCLC.

Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Shandong Cancer Hospital Affiliated to Shandong University,

Abstract

Association between psychological distress and treatment efficacy in patients with newly diagnosed SCLC.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Second Xiangya Hospital of Central South University, Central South University, Changsha, China,

Abstract

A United Kingdom prospective, multicentre, observational cohort study investigating tolerance of anti-cancer systemic therapy in the elderly: The TOASTIE study.

Org: The Beatson West of Scotland Cancer Centre, Freeman Hospital, NHS, Northern Ireland Cancer Centre, Singleton Hospital, Respiratory Department, Northumbria Healthcare NHS Foundation Trust,

Abstract

Effect of perioperative medical therapy on prognosis in recurrent nasopharyngeal carcinoma: A comparative effectiveness research.

Org: Eye & ENT Hospital, EENT Hospital,

Abstract

PD-(L)1 inhibitors plus anlotinib: A superior option for second-line treatment of extensive-stage small cell lung cancer.

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University,

Product

Chemotherapy (dacarbazine or paclitaxel)